We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Surgical Innovations Group Plc | LSE:SUN | London | Ordinary Share | GB0004016704 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.50 | 0.40 | 0.60 | 0.50 | 0.50 | 0.50 | 72,931 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Surgical,med Instr,apparatus | 11.34M | 264k | 0.0003 | 16.67 | 4.66M |
TIDMSUN
RNS Number : 4650C
Surgical Innovations Group PLC
21 June 2021
Surgical Innovations Group plc
("the Company" or "the Group")
Withdrawal of AGM Resolution
Surgical Innovations Group plc (AIM: SUN) advises that it has withdrawn Resolution 7 from the agenda of the Annual General Meeting ("AGM") of the Company's shareholders scheduled to be held at 12:00 noon tomorrow (22 June 2021).
Resolution 7 was a special resolution enabling, inter alia, the prospective allotment of new shares as if section 561(1) of the Companies Act did not apply to any such allotment, i.e. as if pre-emption rights did not apply. This resolution has been withdrawn following indications from a small number of significant shareholders in the Company that they do not support this resolution.
The withdrawal of this item of business does not affect the validity of the remainder of the resolutions to be proposed at the AGM, or that of proxy votes already submitted in respect of the remaining resolutions to be put to shareholders for approval at the meeting. The numbering of all other proposed resolutions at the AGM remains unchanged.
The withdrawal of Resolution 7 does not affect the strategy or the day-to-day running of the business and the Directors do not currently envisage that the business would need to raise new funds through the issue of new shares before the 2022 AGM. Should such need arise, a separate general meeting would be convened to seek shareholder approval at the relevant time.
Arrangements for the AGM are unchanged from those previously notified.
For further information please contact:
Surgical Innovations Group plc www sigroupplc com David Marsh, CEO Tel: 0113 230 7597 Charmaine Day, Co Sec & GFC N+1 Singer (Nominated Adviser Tel: 020 7496 3000 & Broker) Aubrey Powell / Rachel Hayes/ Iqra Amin Walbrook PR (Financial PR & Investor Tel: 020 7933 8780 or si@walbrookpr.com Relations) Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391 303
About Surgical Innovations Group plc
The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.
We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part re-usable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.
Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.
In addition, we design and develop medical devices for carefully selected OEM partners, and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.
We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs in the operating theatre environment.
The Group currently employs approximately 100 people across two sites in the UK. Product design, engineering and manufacturing are carried out at the SI site in Yorkshire. Commercial activities including marketing, UK distribution and international sales and marketing are based at Elemental Healthcare in Berkshire.
Further information
Further details of the Group's businesses and products are available on the following websites:
www sigroupplc com
www surginno com
www elementalhealthcare co.uk
To receive regular updates by email, please contact si@walbrookpr.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCPPUUWQUPGGMU
(END) Dow Jones Newswires
June 21, 2021 02:00 ET (06:00 GMT)
1 Year Surgical Innovations Chart |
1 Month Surgical Innovations Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions